• Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) said the modified vaccine against the omicron coronavirus variant generated a higher immune response.

• The companies said that 30 µg and 60 µg doses of a shot targeting just the BA.1 omicron subvariant elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against that subvariant.

• Also Read: Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Nod For Kids As Young As Six Months.

• A version of the shot that contained both the redesigned vaccine and their original vaccine elicited a 9.1 and 10.9-fold increase.

• The results were from a trial of 1,234 people aged 56 or older. The shots were well-tolerated in participants, the companies said.

• Early laboratory studies suggest that both Omicron-modified candidates neutralize the omicron BA.4 and BA.5 subvariants, though to a lesser extent than they do for BA.1, with titers approximately 3-fold lower.

• The companies will continue to collect additional study data on Omicron BA.4/BA.5 over the coming weeks.

• Price Action: PFE shares are down 0.02% at $51.60, and BNTX stock is up 3.07% at $138.15 during the premarket session on the last check Monday.

• Image by x3 from Pixabay

See more from Benzinga

• The Daily Biotech Pulse: European Backing For Novavax's COVID-19 Shot In Adolescents, Sanofi-GSK's Updated Vaccine Effective Against Omicron, FDA's Clinical Hold On Sarepta's Duchenne Trial

• The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.